STOCK TITAN
  1. Home
  2. Sec-filings
  3. FENC
  4. [144] FENNEC PHARMACEUTICALS INC. SEC Filing

Fennec Pharma officer plans $146K stock sale

FENNEC PHARMACEUTICALS INC.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. (FENC) received a Form 144 notice from officer Pierre S. Sayad covering a proposed sale of 12,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The notice cites an aggregate market value of $146,169.60 and references 35,067,159 common shares outstanding. The shares relate to performance shares and restricted stock scheduled to vest in 2026.

Positive

  • None.

Negative

  • None.
Shares to be sold 12,000 shares of common stock Proposed Rule 144 sale through Morgan Stanley Smith Barney LLC
Aggregate market value of shares to be sold $146,169.60 Value associated with the 12,000 common shares in the Form 144
Shares outstanding 35,067,159 shares Common shares outstanding referenced in the Form 144 notice
Performance Shares 11,157 shares Performance Shares of common stock dated 03/31/2026
Restricted Stock tranche 171 shares Restricted Stock of common stock dated 03/31/2026
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Performance Shares financial
"Common | 03/31/2026 | Performance Shares | Issuer"
Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.
Restricted Stock financial
"Common | 03/31/2026 | Restricted Stock | Issuer"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Aggregate market value financial
"Common | Morgan Stanley Smith Barney LLC ... | 12000 | 146169.60"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 filing for FENC disclose about planned share sales?
It discloses that officer Pierre S. Sayad has notified of a proposed sale of 12,000 shares of FENNEC PHARMACEUTICALS INC. common stock, with an indicated aggregate market value of $146,169.60, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

How many FENC shares are outstanding according to this Form 144?
The notice lists 35,067,159 shares of FENNEC PHARMACEUTICALS INC. common stock as outstanding in connection with the proposed Rule 144 sale disclosure.

What types of equity awards underlie the FENC shares in this Form 144?
The securities to be sold include Performance Shares and Restricted Stock in FENNEC PHARMACEUTICALS INC., with specific tranches scheduled on dates in 2026 such as 03/31/2026, 04/30/2026, and later months.

How many FENC performance shares are referenced in the Form 144 filing?
The filing lists 11,157 Performance Shares of FENNEC PHARMACEUTICALS INC. common stock with a date of 03/31/2026 in the section describing securities to be sold.

Which broker is named in the FENC Form 144 filing?
The proposed sale of 12,000 FENC common shares is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, in connection with trading on NASDAQ.

Who is the person for whose account FENC shares are to be sold under this Form 144?
The person for whose account the securities are to be sold is Pierre S. Sayad, identified as an Officer of FENNEC PHARMACEUTICALS INC., as stated in the Rule 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR